Adaptimmune Therapeutics plc, a leader in cell therapy for the treatment of solid tumor cancers, has finalized a notable $125 million term loan facility with Hercules Capital. The financing agreement, advised by Ropes & Gray, is designed to fortify Adaptimmune’s balance sheet as it accelerates its sarcoma franchise, with a commercial launch planned for 2026. The term loan will be available in up to five tranches with the first $25 million already drawn and further tranches subject to specific conditions. This strategic move underscores Adaptimmune’s commitment to advancing cancer treatments and reflects confidence from key financial partners.

Healthcare, Finance, Legal Advisory,United Kingdom, United States